<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00160459</url>
  </required_header>
  <id_info>
    <org_study_id>M99-144</org_study_id>
    <nct_id>NCT00160459</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety and Efficacy of Asoprisnil (J867) in Patients With Uterine Leiomyomata.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine the safety and effectiveness of 3 asoprisnil doses
      compared to placebo, taken for 12 weeks by women with uterine fibroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No medical therapy is currently available for the long-term treatment of uterine fibroids.
      The objective of this study is to determine the safety and efficacy of asoprisnil 5 mg, 10 mg
      and 25 mg, compared to placebo, taken daily for 12 weeks by women with one or more uterine
      fibroids, confirmed by ultrasound. Upon completion, subjects at participating sites will be
      allowed to enter an open-label extension study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in uterine volume and volume of the largest fibroid.</measure>
    <time_frame>Treatment weeks 4, 8, 12 and Post-treatment months 3 and 6.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of amenorrhea</measure>
    <time_frame>Day 1 to 1st post treatment menses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in uterine size in gestational weeks.</measure>
    <time_frame>Treatment weeks 4, 8, 12 and Post-treatment months 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects in each treatment group achieving&gt; or = to 20% reduction in uterine volume.</measure>
    <time_frame>Week 12 and final visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of days with bleeding.</measure>
    <time_frame>Day 1 through end of 1st post-treatment menses</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hematologic and iron parameters.</measure>
    <time_frame>Baseline to each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine fibroid symptom improvement.</measure>
    <time_frame>Baseline to each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Global Efficacy Question regarding improvement in fibroid symptoms.</measure>
    <time_frame>Week 12 and Final Visit</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>5 mg Tablet, oral Daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>10 mg Tablet, oral Daily for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asoprisnil</intervention_name>
    <description>25 mg Tablet, oral Daily for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, oral Daily for 12 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 18 and 49 years of age

          -  Diagnosis of either 1 or more uterine fibroids

          -  History of regular menstrual cycles of 21 to 35 days in length.

        Exclusion Criteria:

          -  Any abnormal lab result the study-doctor considers significant

          -  History of severe reaction to or current use of hormone therapy

          -  History of osteoporosis or other bone disease

          -  History of uterine artery embolization, cryomyolysis, or electrical myolysis

          -  Subject currently breast feeding

          -  Hemoglobin &lt; 8 g/dL at baseline
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <results_reference>
    <citation>Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril. 2007 Jun;87(6):1399-412. Epub 2007 Feb 20.</citation>
    <PMID>17307170</PMID>
  </results_reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>May 27, 2008</last_update_submitted>
  <last_update_submitted_qc>May 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cynthia Mattia-Goldberg</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Fibroid Uterus</keyword>
  <keyword>Leiomyoma</keyword>
  <keyword>Uterine Fibroids</keyword>
  <keyword>asoprisnil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

